Making the Case for Accelerated Withdrawal of Aducanumab
Manuscript Number:
22-0262R1
Author(s):
G. Caleb Alexander, Jerry Avorn, Shannon Brownlee, Cameron Camp, Howard Chertkow, Adriane Fugh-Berman, Sam Gandy, Daniel R. George, Robert Howard, Aaron Kesselheim, Kenneth M. Langa, Eric B. Larson, George Perry, Edo Richard, Vikas Saini, Lon Schneider, Peter Whitehouse
Disclosures
G. Caleb Alexander
Consulting Fees:
Dr. Alexander is past Chair and a current member of FDA’s Peripheral and Central Nervous System Advisory Committee; is a co-founding Principal and equity holder in Monument Analytics, a health care consultancy whose clients include the life sciences industry as well as plaintiffs in opioid litigation; and is a past member of OptumRx’s National P&T Committee. This arrangement has been reviewed and approved by Johns Hopkins University in accordance with its conflict of interest policies.
Equity:
Dr. Alexander is past Chair and a current member of FDA’s Peripheral and Central Nervous System Advisory Committee; is a co-founding Principal and equity holder in Monument Analytics, a health care consultancy whose clients include the life sciences industry as well as plaintiffs in opioid litigation; and is a past member of OptumRx’s National P&T Committee. This arrangement has been reviewed and approved by Johns Hopkins University in accordance with its conflict of interest policies.
Patents/Royalties
Dr. Alexander is past Chair and a current member of FDA’s Peripheral and Central Nervous System Advisory Committee; is a co-founding Principal and equity holder in Monument Analytics, a health care consultancy whose clients include the life sciences industry as well as plaintiffs in opioid litigation; and is a past member of OptumRx’s National P&T Committee. This arrangement has been reviewed and approved by Johns Hopkins University in accordance with its conflict of interest policies.
Jerry Avorn
Nothing to Disclose
Shannon Brownlee
Nothing to Disclose
Cameron Camp
Nothing to Disclose
Howard Chertkow
Grants
Agency:
Hoffmann-La Roche Limited
Dates:
2019-2022
Agency:
Lilly
Dates:
2021-2022
Agency:
Abbvie Corporation
Dates:
2018-2020
Agency:
Alector Co
Dates:
2021-2022
Agency:
Anavex Life Sciences
Dates:
2022
Agency:
Immunocal
Dates:
2018-2022
Adriane Fugh-Berman
Patents/Royalties
I am an expert witness on behalf of plaintiffs in litigation regarding pharmaceutical marketing practices. I have done no expert witness work on Alzheimer's drugs. My project at Georgetown University Medical Center receives some funding from Kaiser Permanente.
I have a patent on a mint mask for asthma and bronchitis. There is no commercial sponsor and that is unrelated to this subject.
Sam Gandy
Nothing to Disclose
Daniel R. George
Nothing to Disclose
Robert Howard
Nothing to Disclose
Aaron Kesselheim
Nothing to Disclose
Kenneth M. Langa
Consulting Fees:
I receive consulting fees for work on University-based NIH-funded research projects. I do not receive consulting fees from any for-profit company.
Health Data Analytics Institute (privately held) 1%
The rest are all publicly traded in my retirement account:
Mosaic Industries 1500
Nel Inc 236,000
ITM Power 23,500
Enapter 1100
Etsy 100
Lon Schneider
Consulting Fees:
Eli Lilly, Neurim, Ltd, Cognition Therapeutics, Takeda, vTv, Roche/Genentech, Samus, Immunobrain Checkpoint, Biovie, Cortexyme, AC Immune, GW Research, Otsuka, Pharmatrophix, Alpha Cognition, Novo Nordisk, UCB, Vivli.org